Medicago prices overnight offering

Medicago (TSX:MDG) has carried out an overnight marketed offering and agreed to sell up to 34,117,600 units at a price of 51 cents a unit to raised $17.4 million. Each unit is comprised of one common share and one-quarter of a warrant, with each whole warrant exercisable to purchase another common share for 75 cents [...]

IMRIS prices $52.5 million offering

IMRIS (TSX:IM; NASDAQ:IMRS) priced a public offering of 10.5 million common shares at $5 (U.S.) a share to raise $52.5 million in connection with listing its shares on the NASDAQ Global Market. An additional 500,000 shares are being sold by a certain selling shareholder of IMRIS at the same price. Canaccord Genuity and Lazard Capital [...]

IMRIS to list on Nasdaq and sell stock

IMRIS (TSX:IM) has filed a registration statement as part of an IPO in the U.S. and has received conditional approval to list its common shares on the NASDAQ Global Market under the symbol IMRS. IMRIS proposes to offer 10 million common shares and certain selling shareholders propose to offer 3.7 million shares through a syndicate [...]

Oncolytics in $25 million bought deal

A group of underwriters have agreed to purchase 5.44 million units of Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY) in a bought deal at a price of $4.60 each for total proceeds of about $25 million. Each unit consists of one common share and one-half of a warrant, with each whole warrant entitling the holder to buy an [...]

Immunovaccine in unit offering

Immunovaccine (TSX-V:IMV) has filed a short-form prospectus to raise a minimum of $6.5 million and a maximum of $8 million through the sale of units priced at $1 each. Each unit consists of one common share and one-half of a warrant, with each whole warrant entitling the holder to purchase one additional common share at [...]

Medicago offers $7 million of units

Medicago (TSX:MDG) has entered into an agency agreement and carried out an overnight marketed offering to sell up to 17,283,952 units at a price of 40.5 cents each in order to finance its $7.5 million share of a new U.S. pandemic vaccine plant that includes a grant from an arm of the U.S. Department of [...]

Paradigm starts Immunovaccine at buy

Paradigm Capital has initiated coverage of Immunovaccine (TSX-V:IMV) with a “buy” and 12-month price target of $2.50.  The stock closed at $1.30 on Friday. Analyst Claude Camire writes that his target price is based on the sum of the risk-adjusted asset value for the company’s veterinary vaccines of about 75 cents a share and its [...]